Jolene M. Singh

Oct 23, 2023 | nature.com | Anne Reiner |Andrew Seidman |Sarat Chandarlapaty |Jolene M. Singh

AbstractThe HER2-directed antibody-drug conjugate trastuzumab deruxtecan is active against lower levels of HER2 expression than prior-generation therapies. The rate of HER2 expression in brain metastases among patients with initially HER2-null breast cancer is undefined, and receptor discordance in advanced breast cancer with brain metastases may underestimate CNS response potential in the absence of brain metastasis sampling.